Saudi Biotech Startup NanoPalm: Revolutionizing Gene Therapy for Sickle Cell Disease with AI, Nanotechnology, and Gene Editing
NanoPalm, a Saudi-based biotech company founded in 2022 and headquartered in Riyadh, is developing a biorobot using AI, nanotechnology, and gene therapy to address sickle cell disease.
Affecting around 20 million people globally, sickle cell disease is a genetic disorder causing crescent-shaped, rigid red blood cells, leading to blocked blood vessels, pain, fatigue, and anemia.
NanoPalm started at the King Abdulaziz City for Science and Technology (KACST) and was incubated by the NextEra initiative.
The team spent over a year gathering data for AI models.
NanoPalm, run by the Ministry of Communication and Information Technology in partnership with The Garage, a 28,000-square-meter space for 300 startups.
Ali Al-Hasan and Samar Al-Sudir, the founders of NanoPalm, are using their expertise in nanomedicine and chemistry to develop a groundbreaking product for sickle cell treatment.
Instead of just treating symptoms, their goal is to remove the sickle cell gene from a patient's body.
The team spent over a year collecting data for artificial intelligence models to predict the most effective and safe gene therapies, reducing therapy duration and making it affordable.
Nanobots are used to repair damaged DNA.
The text discusses the drug development process in pharma companies, specifically focusing on NanoPalm's approach.
NanoPalm utilizes three technologies: AI for modeling and prediction, nanotechnology for creating medicines, and gene therapy for editing genetic material.
The AI generates a manufacturing recipe, which is then used to create lipid biorobots in the lab.
These biorobots encapsulate genetic materials, such as mRNA, that act like scissors to remove specific genes.
Patients receive an IV infusion of these biorobots for four hours at the clinic and then go home.
(Opinion) The text compares the lipid biorobots to vehicles that encapsulate genetic materials, acting like scissors to remove targeted genes.
NanoPalm, a biotech company, aims to revolutionize the industry by developing biorobots to detect and treat sickle cell disease and other genetic diseases with no known cures.
Sickle cell disease causes "sickle" shaped red blood cells.
NanoPalm uses AI, nanotechnology, and gene therapy to make treatments more cost-effective.
They found that sickle cell disease is just one of over 6,000 genetic diseases and current gene therapies are ineffective and extremely expensive.
The company's biorobots use AI to navigate and find diseased cells, nanotechnology to create the medicine, and gene therapy to edit genetic material.
NanoPalm is working with KACST, King Saud University, and the National Guard Hospital in Saudi Arabia to treat 15 sickle cell patients using their technology.
The product, which is expected to be launched in 2030, has the potential to benefit around 42,000 Saudis with sickle cell disease.
NanoPalm started at the King Abdulaziz City for Science and Technology (KACST) and was incubated by the NextEra initiative.
The team spent over a year gathering data for AI models.
NanoPalm, run by the Ministry of Communication and Information Technology in partnership with The Garage, a 28,000-square-meter space for 300 startups.
Ali Al-Hasan and Samar Al-Sudir, the founders of NanoPalm, are using their expertise in nanomedicine and chemistry to develop a groundbreaking product for sickle cell treatment.
Instead of just treating symptoms, their goal is to remove the sickle cell gene from a patient's body.
The team spent over a year collecting data for artificial intelligence models to predict the most effective and safe gene therapies, reducing therapy duration and making it affordable.
Nanobots are used to repair damaged DNA.
The text discusses the drug development process in pharma companies, specifically focusing on NanoPalm's approach.
NanoPalm utilizes three technologies: AI for modeling and prediction, nanotechnology for creating medicines, and gene therapy for editing genetic material.
The AI generates a manufacturing recipe, which is then used to create lipid biorobots in the lab.
These biorobots encapsulate genetic materials, such as mRNA, that act like scissors to remove specific genes.
Patients receive an IV infusion of these biorobots for four hours at the clinic and then go home.
(Opinion) The text compares the lipid biorobots to vehicles that encapsulate genetic materials, acting like scissors to remove targeted genes.
NanoPalm, a biotech company, aims to revolutionize the industry by developing biorobots to detect and treat sickle cell disease and other genetic diseases with no known cures.
Sickle cell disease causes "sickle" shaped red blood cells.
NanoPalm uses AI, nanotechnology, and gene therapy to make treatments more cost-effective.
They found that sickle cell disease is just one of over 6,000 genetic diseases and current gene therapies are ineffective and extremely expensive.
The company's biorobots use AI to navigate and find diseased cells, nanotechnology to create the medicine, and gene therapy to edit genetic material.
NanoPalm is working with KACST, King Saud University, and the National Guard Hospital in Saudi Arabia to treat 15 sickle cell patients using their technology.
The product, which is expected to be launched in 2030, has the potential to benefit around 42,000 Saudis with sickle cell disease.
Translation:
Translated by AI
